STOCK TITAN

Point72 entities report 0% ownership in Forte Biosciences (FBRX)

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Forte Biosciences, Inc. Schedule 13G/A amendment shows that Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen reported 0% beneficial ownership of Forte Biosciences common stock as of the close of business on March 31, 2026. The filing lists the reporting persons' principal business address and CUSIP 34962G208.

Positive

  • None.

Negative

  • None.

Insights

Filing confirms no reportable stake by Point72 entities and Mr. Cohen as of March 31, 2026.

The amendment to Schedule 13G/A states the amount beneficially owned and voting/dispositive powers for the reporting persons are set forth on the cover page and are 0% as of March 31, 2026. The document lists the reporting persons' principal business address and the issuer CUSIP.

Because this is an ownership disclosure showing 5% or less ownership, it is routine; subsequent filings would show any material change in ownership.

Beneficial ownership 0% as of March 31, 2026
CUSIP 34962G208 Forte Biosciences common stock
Signature date 05/15/2026 Authorized Person signature date
Schedule 13G/A regulatory
"Amendment No. 1 to Schedule 13G/A is the form type filed"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficially owned regulatory
"Amount beneficially owned: The information required by Item 4(a) is set forth"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
dispositive power regulatory
"Sole Dispositive Power / Shared Dispositive Power entries listed on cover page"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does the Forte Biosciences (FBRX) Schedule 13G/A amendment say?

It states that Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen reported 0% beneficial ownership of Forte Biosciences common stock as of March 31, 2026. The filing provides the reporting persons' business address and CUSIP 34962G208.

Does the filing indicate Point72 or Steven A. Cohen own shares of FBRX?

No; the filing reports 0% beneficial ownership for the listed reporting persons as of the close of business on March 31, 2026. It incorporates cover-page ownership rows by reference rather than listing a share count in the text.

What is the significance of a Schedule 13G/A showing 0% ownership for FBRX?

A Schedule 13G/A with 0% ownership indicates the reporting persons do not hold reportable positions above the 5% threshold as of the stated date. This is a routine ownership disclosure rather than an acquisition or disposition event.

Who filed the amendment on behalf of Point72 and how is it signed?

The statement is filed on behalf of Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen. It is signed by Jason M. Colombo as Authorized Person, with signature dates shown as May 15, 2026.





34962G208

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:05/15/2026
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:05/15/2026
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:05/15/2026